Outset Medical, Inc. OM
Institutional shares held
17.4 Million
46.5K
calls
57.2K
puts
Total value of holdings
$11M
$29K
calls
$36K
puts
Market Cap
$34.6M
48,007,300
Shares Out.
Institutional ownership
36.22%
# of Institutions
86
We take great care to ensure that the data presented and summarized in this overview for Outset Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OM
View all-
Vanguard Group Inc Valley Forge, PA2.61MShares$1.88 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA1.47MShares$1.06 Million0.08% of portfolio
-
Morgan Stanley New York, NY1.44MShares$1.03 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.39MShares$1 Million0.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT1.29MShares$929,6300.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.01MShares$724,6670.0% of portfolio
-
C World Wide Group Holding A1MShares$720,0000.01% of portfolio
-
Gsa Capital Partners LLP London, X0959KShares$690,7960.08% of portfolio
-
Black Rock Inc. New York, NY880KShares$633,9320.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny687KShares$494,4580.0% of portfolio
Latest Institutional Activity in OM
Top Purchases
Top Sells
About OM
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Insider Transactions at OM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2025
|
Leslie Trigg Chair and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
625,000
+50.0%
|
-
|
|
Mar 10
2025
|
Karen Drexler Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
31,250
+50.0%
|
-
|
|
Mar 10
2025
|
Brent D. Lang Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
250,000
+50.0%
|
-
|
|
Mar 10
2025
|
D Keith Grossman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
187,500
+49.32%
|
-
|
|
Mar 10
2025
|
Patrick T Hackett Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,875,000
+50.0%
|
-
|
|
Mar 10
2025
|
Patrick T Hackett Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250,000
+49.16%
|
-
|
|
Feb 18
2025
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
14,611
-1.63%
|
$0
$0.9 P/Share
|
|
Feb 18
2025
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
6,145
-3.39%
|
$0
$0.9 P/Share
|
|
Feb 18
2025
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
4,204
-2.05%
|
$0
$0.9 P/Share
|
|
Feb 18
2025
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,659
-3.34%
|
$0
$0.9 P/Share
|
|
Jan 21
2025
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
65,236
-2.3%
|
$0
$0.8 P/Share
|
|
Jan 21
2025
|
Nabeel Ahmed Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
34,288
-3.96%
|
$0
$0.8 P/Share
|
|
Jan 21
2025
|
John L. Brottem General Counsel |
SELL
Open market or private sale
|
Direct |
32,930
-5.21%
|
$0
$0.8 P/Share
|
|
Jan 21
2025
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
23,221
-2.56%
|
$0
$0.8 P/Share
|
|
Jan 17
2025
|
Leslie Trigg Chair and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
99,419
+9.38%
|
-
|
|
Jan 17
2025
|
Nabeel Ahmed Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,256
+4.33%
|
-
|
|
Jan 17
2025
|
John L. Brottem General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,090
+4.07%
|
-
|
|
Jan 17
2025
|
Marc Nash SVP Operations and R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,898
+1.28%
|
-
|
|
Jan 13
2025
|
Leslie Trigg Chair and CEO |
SELL
Open market or private sale
|
Direct |
33,227
-3.71%
|
$0
$0.81 P/Share
|
|
Jan 13
2025
|
Marc Nash SVP Operations and R&D |
SELL
Open market or private sale
|
Direct |
15,011
-6.33%
|
$0
$0.81 P/Share
|
Last 12 Months Summary
Buy / Acquisition
4.59M
Shares
From
16
Insiders
| Grant, award, or other acquisition | 303K shares |
|---|---|
| Exercise of conversion of derivative security | 4.29M shares |
Sell / Disposition
403K
Shares
From
6
Insiders
| Open market or private sale | 403K shares |
|---|